A LITERATURE REVIEW OF SGLT2 INHIBITORS IMPACT ON MAJOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER AND PARKINSON DISEASE
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6010Keywords:
SGLT2, Sodium-Glucose Cotransporter-2 Inhibitors, Alzheimer Disease, Parkinson DiseaseAbstract
SGLT2i (sodium-glucose cotransporter 2 inhibitors), also called flozins or gliflozins, are a group of hypoglycemic agents that have revolutionized the approach in treatment of T2DM (type 2 diabetes mellitus). Recent years have witnessed a rise in number of neurological conditions, which requires novel approaches to be examined to provide neuroprotection in these patients. Some studies suggest that presence of SGLT2 receptors in the central nervous system can provide possible neuroprotective properties in Alzheimer and Parkinson disease with the use of SGLT2i. We aimed in this review to summarize current evidence of SGLT2i impact on the central nervous system (CNS), as well to define their potential role in the comprehensive management of patients with neurologic disorders.
Methods and materials: A qualitative synthesis of the data focusing on SGLT2 inhibitors, Alzheimer and Parkinson disease was performed. This literature review of SGLT2 inhibitors effect on neuroprotection in neurodegenerative disorders included recent publications, primarily from the past 10 years, and was conducted from November 2023 to May 2026 using the PubMed database.
We performed a systematic search using specific keywords and medical subject headings (MeSH terms) related to SGLT2 inhibitors, Alzheimer and Parkinson disease. The primary search terms were: “SGLT2 inhibitors”, “sodium-glucose cotransporter 2 inhibitors”, “Alzheimer disease”, “Parkinson disease”, “neuroprotection”, “mild cognitive impairment”, and “flozins”. The criteria for inclusion of articles were as follows: published before May 2026, written in English, peer-reviewed original research articles. Exclusion criteria included publications not available in full text, articles in languages other than English. Editorials, commentaries, and conference abstracts without full data were also excluded. Titles and abstracts of the retrieved articles were screened to determine eligibility based on the inclusion and exclusion criteria.
References
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021). Neuroprotective effect of SGLT2 inhibitors. Molecules, 26(23), 7213. https://doi.org/10.3390/molecules26237213
Singh, A. G. K., Unnikrishnan, A., Zargar, A. H., Kumar, A., Das, A. K., Saboo, B., Sinha, B., Gangopadhyay, K. K., Talwalkar, P. G., Ghosal, S., Kalra, S., Joshi, S., Sharma, S. K., Sriram, U., Mohan, V., et al. (2019). Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Therapy, 10. https://doi.org/10.6084/m9.figshare.7546997
Ni, L., et al. (2020). SGLT2i: Beyond the glucose-lowering effect. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01071-y
Kahn, S. E. (2022). Standards of care in diabetes—2023. Diabetes Care, 46(1). https://diabetesjournals.org/care
Rieg, T., & Vallon, V. (2018). Development of SGLT1 and SGLT2 inhibitors. Diabetologia, 61(10), 2079–2086. https://doi.org/10.1007/s00125-018-4654-7
Skrabic, R., et al. (2022). SGLT2 inhibitors in chronic kidney disease: From mechanisms to clinical practice. Biomedicines, 10(10), 2458. https://doi.org/10.3390/biomedicines10102458
Salvatore, T., et al. (2022). An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. International Journal of Molecular Sciences, 23(7). https://doi.org/10.3390/ijms23073651
Wright, E. M. (2021). SGLT2 inhibitors: Physiology and pharmacology. Kidney360, 2(12), 2027–2037. https://doi.org/10.34067/kid.0002772021
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018). Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. https://doi.org/10.1007/s00125-018-4656-5
Saisho, Y. (2020). SGLT2 inhibitors: The star in the treatment of type 2 diabetes? Diseases, 8(2), 14. https://doi.org/10.3390/diseases8020014
Onishi, A., et al. (2020). A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. American Journal of Physiology-Renal Physiology, 319, 712–728. https://doi.org/10.1152/ajprenal.00264.2020
Wiciński, M., Wódkiewicz, E., Górski, K., Walczak, M., & Malinowski, B. (2020). Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: Focus on Alzheimer’s disease and ischemia-related brain injury. Pharmaceuticals, 13(11), 379. https://doi.org/10.3390/ph13110379
Chiba, Y., Sugiyama, Y., Nishi, N., Nonaka, W., Murakami, R., & Ueno, M. (2020). Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains. Neuropathology, 40(5), 482. https://doi.org/10.1111/neup.12665
Pearson, A., et al. (2020). Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients. BMC Neurology, 20(1). https://doi.org/10.1186/s12883-020-01849-3
Koepsell, H. (2020). Glucose transporters in brain in health and disease. Pflügers Archiv - European Journal of Physiology, 472(9), 1299–1343. https://doi.org/10.1007/s00424-020-02441-x
Nakhal, M. M., Aburuz, S., Sadek, B., & Akour, A. (2022). Repurposing SGLT2 inhibitors for neurological disorders: A focus on the autism spectrum disorder. Molecules, 27(21), 7174. https://doi.org/10.3390/molecules27217174
Servier. (n.d.). SMART—Servier Medical ART. Retrieved December 6, 2022, from https://smart.servier.com/
Dong, M., Wen, S., & Zhou, L. (2022). The relationship between the blood-brain barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 2583–2597. https://doi.org/10.2147/DMSO.S375559
Oerter, S., Förster, C., & Bohnert, M. (2019). Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation. International Journal of Legal Medicine, 133(4), 1107–1114. https://doi.org/10.1007/s00414-018-1893-6
You, Y., et al. (2021). The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Acta Diabetologica, 58(6), 671–685. https://doi.org/10.1007/s00592-020-01648-9
de Matos, A. M., de Macedo, M. P., & Rauter, A. P. (2018). Bridging type 2 diabetes and Alzheimer’s disease: Assembling the puzzle pieces in the quest for the molecules with therapeutic and preventive potential. Medical Research Reviews, 38(1), 261–324. https://doi.org/10.1002/med.21440
Niu, H., Álvarez-Álvarez, I., Guillén-Grima, F., & Aguinaga-Ontoso, I. (2017). Prevalence and incidence of Alzheimer’s disease in Europe: A meta-analysis. Neurología, 32(8), 523–532. https://doi.org/10.1016/j.nrl.2016.02.016
Guerreiro, R., & Bras, J. (2015). The age factor in Alzheimer’s disease. Genome Medicine, 7(1), 1–3. https://doi.org/10.1186/s13073-015-0232-5
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes, 53(2), 474–481. https://doi.org/10.2337/diabetes.53.2.474
Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., & Gong, C. X. (2011). Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. The Journal of Pathology, 225(1), 54. https://doi.org/10.1002/path.2912
Alagiakrishnan, K., & Sclater, A. (2012). Psychiatric disorders presenting in the elderly with type 2 diabetes mellitus. The American Journal of Geriatric Psychiatry, 20(8), 645–652. https://doi.org/10.1097/JGP.0B013E31823038DB
Chen, Z., & Zhong, C. (2014). Oxidative stress in Alzheimer’s disease. Neuroscience Bulletin, 30(2), 271–281. https://doi.org/10.1007/s12264-013-1423-y
Akiyama, H., et al. (2000). Inflammation and Alzheimer’s disease. Neurobiology of Aging, 21(3), 383–421. https://doi.org/10.1016/S0197-4580(00)00124-X
Kellar, D., & Craft, S. (2020). Brain insulin resistance in Alzheimer’s disease and related disorders: Mechanisms and therapeutic approaches. The Lancet Neurology, 19(9), 758–766. https://doi.org/10.1016/S1474-4422(20)30231-3
Zenaro, E., Piacentino, G., & Constantin, G. (2017). The blood-brain barrier in Alzheimer’s disease. Neurobiology of Disease, 107, 41–56. https://doi.org/10.1016/j.nbd.2016.07.007
Avgerinos, K. I., et al. (2022). Empagliflozin induced ketosis, upregulated IGF-1/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics. Cells, 11(21), 3372. https://doi.org/10.3390/cells11213372
Kullmann, S., et al. (2022). Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care, 45(2), 398–406. https://doi.org/10.2337/dc21-1136
Kullmann, S., et al. (2020). Central nervous pathways of insulin action in the control of metabolism and food intake. The Lancet Diabetes & Endocrinology, 8(6), 524–534. https://doi.org/10.1016/S2213-8587(20)30113-3
Laws, S. M., et al. (2017). Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-09577-4
Cunnane, S. C., et al. (2020). Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 19(9), 609–633. https://doi.org/10.1038/s41573-020-0072-x
Youm, Y. H., et al. (2015). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine, 21(3), 263–269. https://doi.org/10.1038/nm.3804
Heneka, M. T., et al. (2013). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature, 493(7434), 674–678. https://doi.org/10.1038/nature11729
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences, 20(13). https://doi.org/10.3390/ijms20133328
Avgerinos, K. I., et al. (2022). Empagliflozin induced ketosis, upregulated IGF-1/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics. Cells, 11(21), 3372. https://doi.org/10.3390/cells11213372
Matthews, D. C., et al. (2021). Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease. Brain, 144(12), 3742–3755. https://doi.org/10.1093/brain/awab222
Lund, T. M., Risa, Ø., Sonnewald, U., Schousboe, A., & Waagepetersen, H. S. (2009). Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. Journal of Neurochemistry, 110(1), 80–91. https://doi.org/10.1111/j.1471-4159.2009.06115.x
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & De La Monte, S. M. (2005). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions in acetylcholine. Journal of Alzheimer’s Disease, 8(3), 247–268. https://doi.org/10.3233/JAD-2005-8304
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015). mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease, 84, 39–49. https://doi.org/10.1016/j.nbd.2015.03.014
Cai, Z., Chen, G., He, W., Xiao, M., & Yan, L. J. (2015). Activation of mTOR: A culprit of Alzheimer’s disease? Neuropsychiatric Disease and Treatment, 11, 1015–1030. https://doi.org/10.2147/NDT.S75717
Perluigi, M., Di Domenico, F., Barone, E., & Butterfield, D. A. (2021). mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radical Biology and Medicine, 169, 382. https://doi.org/10.1016/j.freeradbiomed.2021.04.025
Yuan, H. X., Xiong, Y., & Guan, K. L. (2013). Nutrient sensing, metabolism, and cell growth control. Molecular Cell, 49(3), 379–387. https://doi.org/10.1016/j.molcel.2013.01.019
Nixon, R. A. (2017). Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: Inseparable partners in a multifactorial disease. FASEB Journal, 31(7), 2729–2743. https://doi.org/10.1096/fj.201700359
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019). Tau and mTOR: The hotspots for multifarious diseases in Alzheimer’s development. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01017
Sim, A. Y., Barua, S., Kim, J. Y., Lee, Y. H., & Lee, J. E. (2021). Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus. Frontiers in Neuroscience, 15. https://doi.org/10.3389/fnins.2021.708547
Lin, B., et al. (2014). Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovascular Diabetology, 13(1). https://doi.org/10.1186/s12933-014-0148-1
Ionescu-Tucker, A., & Cotman, C. W. (2021). Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiology of Aging, 107, 86–95. https://doi.org/10.1016/j.neurobiolaging.2021.07.014
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019). Tau and mTOR: The hotspots for multifarious diseases in Alzheimer’s development. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01017
Krabbe, K. S., et al. (2007). Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia, 50(2), 431–438. https://doi.org/10.1007/s00125-006-0537-4
Xie, B., et al. (2020). Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer’s disease and mild cognitive impairment: Results of a meta-analysis. International Journal of Neuroscience, 130(3), 218–230. https://doi.org/10.1080/00207454.2019.1667794
Bharani, K. L., Ledreux, A., Gilmore, A., Carroll, S. L., & Granholm, A. C. (2020). Serum pro-BDNF levels correlate with phospho-tau staining in Alzheimer’s disease. Neurobiology of Aging, 87, 49–59. https://doi.org/10.1016/j.neurobiolaging.2019.11.010
Shaikh, S., et al. (2014). Current acetylcholinesterase-inhibitors: A neuroinformatics perspective. CNS & Neurological Disorders - Drug Targets, 13(3), 391–401. https://doi.org/10.2174/18715273113126660166
Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., & Ribeiro, F. M. (2016). Alzheimer’s disease: Targeting the cholinergic system. Current Neuropharmacology, 14(1), 101–115. https://doi.org/10.2174/1570159X13666150716165726
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016). Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Biotechnology and Applied Biochemistry, 63(1), 145–150. https://doi.org/10.1002/bab.1319
Arafa, N. M. S., Ali, E. H. A., & Hassan, M. K. (2017). Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. Chemico-Biological Interactions, 277, 195–203. https://doi.org/10.1016/j.cbi.2017.08.013
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson’s Disease, 8(Suppl. 1), S3. https://doi.org/10.3233/JPD-181474
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021). Challenges in the diagnosis of Parkinson’s disease. The Lancet Neurology, 20(5), 385–397. https://doi.org/10.1016/S1474-4422(21)00030-2
Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. JAMA, 323(6), 548–560. https://doi.org/10.1001/jama.2019.22360
Weintraub, D., et al. (2022). The neuropsychiatry of Parkinson’s disease: Advances and challenges. The Lancet Neurology, 21(1), 89–102. https://doi.org/10.1016/S1474-4422(21)00330-6
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435–450. https://doi.org/10.1038/nrn.2017.62
Connolly, B. S., & Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: A review. JAMA, 311(16), 1670–1683. https://doi.org/10.1001/jama.2014.3654
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018). Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology, 91(2), e139–e142. https://doi.org/10.1212/WNL.0000000000005771
Cheong, J. L. Y., de Pablo-Fernandez, E., Foltynie, T., & Noyce, A. J. (2020). The association between type 2 diabetes mellitus and Parkinson’s disease. Journal of Parkinson’s Disease, 10(3), 775–789. https://doi.org/10.3233/JPD-191900
Yang, Y. W., et al. (2017). Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine, 96(3). https://doi.org/10.1097/MD.0000000000005921
Sandyk, R. (1993). The relationship between diabetes mellitus and Parkinson’s disease. International Journal of Neuroscience, 69(1–4), 125–130. https://doi.org/10.3109/00207459309003322
Lin, K. J., et al. (2021). Two birds one stone: The neuroprotective effect of antidiabetic agents on Parkinson disease—Focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. Antioxidants, 10(12). https://doi.org/10.3390/antiox10121935
Mousa, H. H., Sharawy, M. H., & Nader, M. A. (2023). Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4. Life Sciences, 312. https://doi.org/10.1016/j.lfs.2022.121258
Motawi, T. K., Al-Kady, R. H., Abdelraouf, S. M., & Senousy, M. A. (2022). Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson’s disease in rats: Targeting the GRP78/PERK/eIF2α/CHOP pathway and miR-211-5p. Chemico-Biological Interactions, 362. https://doi.org/10.1016/j.cbi.2022.110002
Arab, H. H., Safar, M. M., & Shahin, N. N. (2021). Targeting ROS-dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson’s disease rat model. ACS Chemical Neuroscience, 12(4), 689–703. https://doi.org/10.1021/acschemneuro.0c00722
Wiviott, S. D., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 380(4), 347–357. https://doi.org/10.1056/NEJMoa1812389
Cannon, C. P., et al. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. The New England Journal of Medicine, 383(15), 1425–1435. https://doi.org/10.1056/NEJMoa2004967
Steiner, S. (2016). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift für Gefässmedizin, 13(1), 17–18. https://doi.org/10.1056/NEJMoa1504720
Mahaffey, K. W., et al. (2018). Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation, 137(4), 323–334. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
Perkovic, V., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine, 380(24), 2295–2306. https://doi.org/10.1056/NEJMoa1811744
Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with chronic kidney disease. The New England Journal of Medicine, 383(15), 1436–1446. https://doi.org/10.1056/NEJMoa2024816
Nayak, S., Rathore, V., Bharati, J., & Sahu, K. K. (2021). Extending the ambit of SGLT2 inhibitors beyond diabetes: A review of clinical and preclinical studies on non-diabetic kidney disease. Expert Review of Clinical Pharmacology, 14(12), 1513–1526. https://doi.org/10.1080/17512433.2021.2028620
Brown, E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J., & Cuthbertson, D. J. (2021). The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Annals of Medicine, 53(1), 2072–2089. https://doi.org/10.1080/07853890.2020.1841281
Oerter, S., Förster, C., & Bohnert, M. (2019). Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation. International Journal of Legal Medicine, 133(4), 1107–1114. https://doi.org/10.1007/s00414-018-1893-6
Jinnouchi, H., Nozaki, K., Watase, H., Omiya, H., Sakai, S., & Samukawa, Y. (2016). Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus. Advances in Therapy, 33(3), 460–479. https://doi.org/10.1007/s12325-016-0291-z
Wilding, J. P. H., et al. (2012). Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Annals of Internal Medicine, 156(6), 405–415. https://doi.org/10.7326/0003-4819-156-6-201203200-00003
Polidori, D., et al. (2013). Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study. Diabetes Care, 36(8), 2154–2161. https://doi.org/10.2337/dc12-2391
Tyagi, R., Vaidya, B., & Sharma, S. S. (2022). Crosstalk between neurological, cardiovascular, and lifestyle disorders: Insulin and lipoproteins in the lead role. Pharmacological Reports, 74(5), 790–817. https://doi.org/10.1007/s43440-022-00417-5
Li, W., Huang, E., & Gao, S. (2017). Type 1 diabetes mellitus and cognitive impairments: A systematic review. Journal of Alzheimer’s Disease, 57(1), 29–36. https://doi.org/10.3233/JAD-161250
Surkova, E. V., Tanashyan, M. M., Bespalov, A. I., & Naminov, A. V. (2019). Diabetes mellitus and cognitive impairment. Terapevticheskii Arkhiv, 91(10), 112–118. https://doi.org/10.26442/00403660.2019.10.000362
Biessels, G. J., & Despa, F. (2018). Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. Nature Reviews Endocrinology, 14(10), 591–604. https://doi.org/10.1038/s41574-018-0048-7
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017). Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(5), 1037–1045. https://doi.org/10.1016/j.bbadis.2016.04.017
Zhou, R., et al. (2021). PET imaging of neuroinflammation in Alzheimer’s disease. Frontiers in Immunology, 12, 1–16. https://doi.org/10.3389/fimmu.2021.739130
Dhapola, R., Hota, S. S., Sarma, P., Bhattacharyya, A., Medhi, B., & Reddy, D. H. K. (2021). Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology, 29(6), 1669–1681. https://doi.org/10.1007/s10787-021-00889-6
Parhizkar, S., & Holtzman, D. M. (2022). APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease. Seminars in Immunology, 59, 101594. https://doi.org/10.1016/j.smim.2022.101594
Leng, F., & Edison, P. (2021). Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nature Reviews Neurology, 17(3), 157–172. https://doi.org/10.1038/s41582-020-00435-y
Karran, M., et al. (2019). Recruitment of older veterans with diabetes risk for Alzheimer’s disease for a randomized clinical trial of computerized cognitive training. Journal of Alzheimer’s Disease, 69(2), 401–411. https://doi.org/10.3233/JAD-180952
Diniz Pereira, J., Gomes Fraga, V., Morais Santos, A. L., Carvalho, M. das G., Caramelli, P., & Braga Gomes, K. (2021). Alzheimer’s disease and type 2 diabetes mellitus: A systematic review of proteomic studies. Journal of Neurochemistry, 156(6), 753–776. https://doi.org/10.1111/jnc.15166
Burillo, J., et al. (2021). Insulin resistance and diabetes mellitus in Alzheimer’s disease. Cells, 10(5), 1236. https://doi.org/10.3390/cells10051236
Moran, G. M., Bakhai, C., Song, S. H., & Agwu, J. C. (2022). Type 2 diabetes: Summary of updated NICE guidance. BMJ. https://doi.org/10.1136/bmj.o775
National Institute for Health and Care Excellence. (n.d.). Recommendations for research: Type 2 diabetes in adults: Management. Retrieved May 25, 2026, from https://www.nice.org.uk/guidance/ng28/chapter/Recommendations-for-research
Introduction and methodology: Standards of care in diabetes—2026. (2026). Diabetes Care, 49(Suppl. 1). https://doi.org/10.2337/DC26-SINT
Davies, M. J., et al. (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. https://doi.org/10.2337/DCI22-0034
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Jucha, Dominik Zając, Dominika Darasz, Artur Łukawski, Lesia Slobozheniuk, Magdalena Bieniak, Marta Kaczorek, Krzysztof Machnik, Oliwia Dziewięcka, Wojciech Ziębka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
